Projects

Protective Vaccine Responses in Infants after Maternal Pertussis Vaccination (PRIME) Study

Christopher Jennifer Peter Blyth Kent Richmond MBBS (Hons) DCH FRACP FRCPA PhD RN MBBS MRCP(UK) FRACP Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and

Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 years

Pertaprime is a study designed to learn more about a new vaccine, called Pertagen®, to protect young adults against pertussis “whooping cough”.

BCG vaccination to Reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure (BRACE) Trial

This trial will determine whether BCG vaccination reduces the incidence and severity of COVID-19 but also whether BCG vaccination reduces other respiratory illnesses in healthcare workers.

ATOMIC Ears: A Phase IIB randomised controlled trial to assess safety, tolerability and acceptability of a 5-day Dornase alfa treatment as an adjunct therapy to ventilation tube insertion for otitis media in children

Chris Jennifer Lea-Ann Peter Ruth Brennan-Jones Kent Kirkham Richmond Thornton PhD RN PhD MBBS MRCP(UK) FRACP PhD Head, Ear and Hearing Health Clinical Research Manager Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead,

A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age

This study aims to investigate a new vaccine which has been developed to protect children from RSV.